On Monday, investor enthusiasm for Scholar Rock (SRRK) drove its stock up more than 6% throughout the trading day, significantly outperforming the S&P 500, which gained just 0.5%. This strong performance was largely attributed to a newly initiated coverage by an analyst, who issued a positive rating that bolstered market confidence in this clinical-stage biotech company.
Even before the market opened, Mani Foroohar, an analyst at Leerink Partners, released a report initiating coverage on Scholar Rock with an “Outperform” rating—equivalent to a “Buy” recommendation—and set a price target of $51 per share. This target implies a potential upside of over 51% from the stock’s recent closing price, reflecting strong optimism about its future performance. Foroohar’s bullish stance is primarily based on the promising development potential of the company’s core drug candidate, Apitegromab. This drug is an adjunctive therapy for spinal muscular atrophy (SMA) and is currently under review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The prospect of regulatory approval has become a key factor driving market confidence.
Additionally, in this first-time coverage report on Scholar Rock, the analyst highlighted the company’s team as having substantial experience in commercializing treatments for rare diseases, even describing it as one of the most specialized teams in the rare disease space among the healthcare stocks he covers. This strength provides crucial support for the company’s future product promotion and market penetration, further reinforcing investors’ optimistic outlook.
If Apitegromab successfully gains approval from either the FDA or the EMA, Scholar Rock will be well-positioned to compete in the SMA treatment landscape. That said, it is important to note that for biotech companies, regulatory approval is only the beginning of commercial success—follow-up challenges such as market adoption and physician acceptance remain. Nevertheless, based on current clinical progress, regulatory status, and team expertise, the company has demonstrated considerable potential, with multiple positive signals adding greater certainty to its future growth trajectory.
